

ANALYSIS OF ANTIRETROVIRAL THERAPY SWITCH IN 2022 IN PEOPLE LIVING WITH HUMAN INMUNODEFICIENCY VIRUS: REASONS AND INMUNOVIROLOGICAL EFFICACY

Pérez García, E; Guerrero Feria, I; López Fernández, A; De España Zaforteza, P; Herrero Collado, L; Sánchez Cerviño, AC; Rivera Ruiz, M; Martín Santamaría, A; De Santiago Álvarez, R; Díaz de Santiago, A; Folguera Olias, C.

HOSPITAL UNIVERSITARIO PUERTA DE HIERRO, MAJADAHONDA, MADRID

WHAT WAS DONE?



To characterize the reasons for switching antiretroviral therapy (ART) in people living with HIV (PLWHIV) in a tertiary-level hospital during 2022



Analysis of the efficacy and safety of the new ART



- PLWHVIV had a fatal outcome due to the complications that resulted from the disease
- There were a reduced therapeutic arsenal for HIV treatment

WHY WAS IT DONE?


MANY REASONS FOR CHANGING **MEDICATION**

- HIV is a chronic disease
- Wide range of drugs, with new mechanisms of action
- Appearance of antimicrobial resistance










Several variables were collected from the electronic prescription program



HOW WAS IT DONE?

Epidemiological: gender, age, nationality





Frecuency distributions

Descriptive statistical



Inmunovirological: plasmatic viral load (PVL), %CD4, CD4/CD8 ratio



84 PLWHIV had changed ART in 2022


- 88,1% was men
- 13,1% have changed ART from a first combination
- HLA B5701 (+) in 3,6%

•	A		-	

WHAT HAS BEEN ACHIEVED?

BEFORE AFTER

BITHERAPY) 26,2% 41,7%





In terms of **efficacy**:

	BEFORE SWITCH	AFTER SWITCH
<50 c/ml PVL	83,3%	91,7%
CD4/CD8 ratio	1,1	2,1

Although the ART was simplified, the efficacy was maintained with no reduction in safety

ART SWITCH REASONS	
REASON	N (%)
Simplification	21 (25)
Adverse effects	19 (22,6)
Virologic failure	13 (15,48)
Other reasons	13 (15,48)
Pharmacological interactions 8 (9,52	
Avoid CR associated with abacavir	7 (8,33)
Enter to a Clinical Trial	3 (3,57)

DISTRIBUTION OF USE OF ANTIRETROVIRAL DRUGS							
BEFORE SWITCH	N (%)	AFTER SWITCH	N (%)				
NNRTIS	23 (27,38)	NNRTIs	13 (15,48)				
Pls	13 (15,48)	Pls	19 (22,62)				
INIs	58 (69,05)	INIs	59 (70,24)				
2 nd generation INI (% respect to total INI)	53/58 (91,38)	2 nd generation INI (% respect to total INI)	59/59 (100)				

**Non-nucleoside reverse transcriptase inhibitors (NNRTIs), Protease inhibitors (Pis), Integrase inhibitors (INIs)



The most common reason for changing ART is **to** simplify it for patient's comfort, with bitherapy being preferable to triple therapy

WHAT IS NEXT?

It is difficult to achieve greater efficacy and safety than oral drugs avaliables nowadays.

However, toxicity remain an important reason of change, althougt adverse effects are not severe



The new lines of research are focused on other formulations like long-acting, instead of improving security o efficacy, in order to improve adherence and reduce stigma

